Comparison Of Long-Term Immunogenicity (23 Y) Of 10 Mu G And 20 Mu G Doses Of Hepatitis B Vaccine In Healthy Children

Qian Wu,Gui-Hua Zhuang,Xue-Liang Wang,Tie-Jun Hou,Dimpy P. Shah,Xiao-Li Wei,Li-Rong Wang,Min Zhang

DOI: https://doi.org/10.4161/hv.20656

2012-01-01

Human Vaccines & Immunotherapeutics

Abstract:To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 mu g or 20 mu g doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a year 11 booster dose and vaccines received outside of the trial, around 50% of participants still maintained anti-HBs titers >= 10 mIU/mL in both 10 mu g and 20 mu g groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and year 11 anti-HBs levels were significantly associated with year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 years with only one transient HBsAg seroconversion in 10 mu g vaccine group. We concluded that seroprotection provided by 10 mu g or 20 mu g doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 mu g or 20 mu g vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.